Astera Cancer Care
Maqsood Amjad, MD, MHCDS, serves as the Chair of the Board of Directors and a Partner Hematologist-Oncologist at Astera Cancer Care since April 2021, contributing to one of New Jersey's leading oncology networks. In addition, Maqsood Amjad holds multiple positions at Robert Wood Johnson University Hospital Hamilton, including Member of the Medical Executive Committee, Chair of the Institutional Review Board, and Section Chief of Medical Oncology, overseeing patient care and research compliance. Additional roles include leading cancer committees at both Robert Wood Johnson University Hospital Somerset and JFK Medical Center, as well as serving as a Consultant Physician across various institutions. Maqsood Amjad's academic credentials include a Master of Health Care Delivery Sciences from Dartmouth and extensive experience in both clinical instruction and administration, fostered through participation in numerous prominent education programs.
This person is not in any teams
This person is not in any offices
Astera Cancer Care
Astera Cancer Care (ACC) is a multispecialty physician practice consisting of medical oncologists, radiation oncologists, and breast surgeons focused on the care of patients with cancer and blood disorders. ACC physicians have cared for thousands of patients in New Jersey since 1981. ACC providers currently practice at 14 distinct locations in Middlesex, Somerset, Hunterdon, Mercer, and Monmouth counties in New Jersey as well as in Bucks County, Pennsylvania. ACC offers standard and advanced therapeutics, including chemotherapy, biologic therapy, immunotherapy and radiopharmaceuticals along with a complete portfolio of radiation oncology treatment options, including proton therapy, prostate brachytherapy, and radiosurgery. The practice is one of the few private groups on the East Coast to offer patients this full array of radiation oncology treatments. Astera has a robust clinical trial platform for cancer therapy with one of the only community-based clinical trial programs in CAR-T cell therapies in the nation. The group is also a leader in value-based oncology care and alternative payment model development.